Kling D, Boldt J, Moosdorf R, Bachmann B, Hempelmann G
Abteilung Anaesthesiologie und operative Intensivmedizin, Klinikum der Justus-Liebig-Universität Giessen.
Anaesthesist. 1988 Apr;37(4):249-55.
Diltiazem is a calcium channel blocker whose effects lie between those of the two other important calcium antagonists nifedipine and verapamil. In addition to vasodilation, it has a negative dromotropic effect with prolongation of the A-V interval. In animal experiments and human investigations, diltiazem improves the function of ischemic myocardium due to a direct dilating effect on coronary vessels. The purpose of the present study was to investigate the hemodynamic effects of diltiazem in patients before and during coronary revascularization. METHODS. The study included 60 consenting male patients with coronary heart disease. Twenty premedicated patients randomly received 0.3 mg/kg diltiazem or placebo within 3 min before induction of anesthesia. Hemodynamic measurements (arterial pressure, heart rate, mean pulmonary arterial pressure, pulmonary capillary pressure, right atrial pressure and cardiac output) were taken during the following 21 min. Before cannulation of the great vessels for institution of extracorporeal circulation (ECC), 20 other patients received 0.014 mg diltiazem or placebo/kg per min over 20 min. In addition to the above mentioned hemodynamic measurements, left ventricular parameters (LVP, LVEDP, dp/dt) were directly registered, and 5 min after the end of ECC the measurements were repeated with the same preload as before the ECC. Twenty additional patients received 0.014 mg diltiazem or placebo/kg per min within 21 min during ECC observing arterial perfusion pressure and oxygenator volume. RESULTS. Pre- and intraoperatively diltiazem caused a decrease in mean arterial pressure; cardiac index increased only during the preoperative investigation period (Tables 1, 2), whereas stroke volume index increased pre- and intraoperatively; heart rate decreased in all patients as well as dp/dt (Fig. 1).(ABSTRACT TRUNCATED AT 250 WORDS)
地尔硫䓬是一种钙通道阻滞剂,其作用介于另外两种重要的钙拮抗剂硝苯地平和维拉帕米之间。除血管舒张作用外,它还具有负性变传导作用,可延长房室间期。在动物实验和人体研究中,地尔硫䓬对冠状动脉血管有直接舒张作用,从而改善缺血心肌的功能。本研究的目的是调查地尔硫䓬在冠状动脉血运重建术前和术中对患者的血流动力学影响。方法:本研究纳入了60例同意参与的男性冠心病患者。20例术前用药患者在麻醉诱导前3分钟内随机接受0.3毫克/千克地尔硫䓬或安慰剂。在接下来的21分钟内进行血流动力学测量(动脉压、心率、平均肺动脉压、肺毛细血管压、右心房压和心输出量)。在大血管插管建立体外循环(ECC)前,另外20例患者在20分钟内接受0.014毫克地尔硫䓬或安慰剂/千克每分钟。除上述血流动力学测量外,直接记录左心室参数(左心室压、左心室舒张末期压、dp/dt),ECC结束后5分钟,以与ECC前相同的前负荷重复测量。另外20例患者在ECC期间的21分钟内接受0.014毫克地尔硫䓬或安慰剂/千克每分钟,观察动脉灌注压和氧合器容量。结果:术前和术中地尔硫䓬均导致平均动脉压下降;仅在术前研究期间心脏指数增加(表1、2),而每搏量指数在术前和术中均增加;所有患者的心率以及dp/dt均下降(图1)。(摘要截短于250字)